Journal: Journal of Enzyme Inhibition and Medicinal Chemistry

Article Title: Ligand-based pharmacophore modelling, structure optimisation, and biological evaluation for the identification of 2-heteroarylthio- N -arylacetamides as novel HSP90 C-terminal inhibitors

doi: 10.1080/14756366.2023.2290912

Figure Lengend Snippet: Representative examples of HSP90 C-terminal inhibitors.

Article Snippet: HSP90α C-Terminal Domain TR-FRET Assay Kit (#50289) was obtained from BPS Bioscience (CA, USA).

Techniques:

Journal: Journal of Enzyme Inhibition and Medicinal Chemistry

Article Title: Ligand-based pharmacophore modelling, structure optimisation, and biological evaluation for the identification of 2-heteroarylthio- N -arylacetamides as novel HSP90 C-terminal inhibitors

doi: 10.1080/14756366.2023.2290912

Figure Lengend Snippet: Ligand-based pharmacophore model. (A) Top-ranked pharmacophore model (pharmacophore_01). Hydrophobic and hydrogen bond acceptor features are coloured blue and green, respectively. (B) Alignments of seven HSP90 C-terminal inhibitors with the pharmacophore_01 model.

Article Snippet: HSP90α C-Terminal Domain TR-FRET Assay Kit (#50289) was obtained from BPS Bioscience (CA, USA).

Techniques:

Journal: Journal of Enzyme Inhibition and Medicinal Chemistry

Article Title: Ligand-based pharmacophore modelling, structure optimisation, and biological evaluation for the identification of 2-heteroarylthio- N -arylacetamides as novel HSP90 C-terminal inhibitors

doi: 10.1080/14756366.2023.2290912

Figure Lengend Snippet: HSP90α C-terminal domain TR-FRET assay. (A) The principle of TR-FRET assay. (B–D) The C-terminal HSP90 activity after the treatment with 9 , 27 , 28 and novobiocin at the indicated concentrations. Novobiocin was evaluated at a concentration of 500 μM. Data represent the mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 by one-way ANOVA compared with vehicle-treated control group.

Article Snippet: HSP90α C-Terminal Domain TR-FRET Assay Kit (#50289) was obtained from BPS Bioscience (CA, USA).

Techniques: Activity Assay, Concentration Assay, Control

Journal: Journal of Enzyme Inhibition and Medicinal Chemistry

Article Title: Ligand-based pharmacophore modelling, structure optimisation, and biological evaluation for the identification of 2-heteroarylthio- N -arylacetamides as novel HSP90 C-terminal inhibitors

doi: 10.1080/14756366.2023.2290912

Figure Lengend Snippet: Western blotting assays. (A) Expression of HSP90, HSP70, ERK, p-AKT in MCF-7 cells after 24 h treatment with 27 ; quantification analysis of detected proteins HSP90 (B), HSP70 (C), ERK (D), and p-AKT (E). Data represent the mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 by one-way ANOVA compared with vehicle-treated control group.

Article Snippet: HSP90α C-Terminal Domain TR-FRET Assay Kit (#50289) was obtained from BPS Bioscience (CA, USA).

Techniques: Western Blot, Expressing, Control

Journal: Journal of Enzyme Inhibition and Medicinal Chemistry

Article Title: Ligand-based pharmacophore modelling, structure optimisation, and biological evaluation for the identification of 2-heteroarylthio- N -arylacetamides as novel HSP90 C-terminal inhibitors

doi: 10.1080/14756366.2023.2290912

Figure Lengend Snippet: Predicted binding modes and interactions of 9 and 27 with HSP90 (PDB ID: 7RY1). (A) Binding pose of 9 and 27 in the HSP90 binding site. 9 and 27 are referred as CPK model. (B) Interactions between 9 and HSP90. (C) Interactions between 27 and HSP90.

Article Snippet: HSP90α C-Terminal Domain TR-FRET Assay Kit (#50289) was obtained from BPS Bioscience (CA, USA).

Techniques: Binding Assay